The need to assess drugs selected from cancer genomic data prior to patient treatment

ISSN： 1741-0541

Source： Personalized Medicine, Vol.9, Iss.5, 2012-07, pp. : 463-466

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Integrating Incident Data from Five Reporting Systems to Assess Patient Safety: Making Sense of the Elephant

By Levtzion-Korach Osnat Frankel Allan Alcalai Hanna Keohane Carol Orav John Graydon-Baker Erin Barnes Janet Gordon Kathleen Puopulo Anne Louise Tomov Elena Ivanova Sato Luke Bates David W.

Joint Commission Journal on Quality and Patient Safety, Vol. 36, Iss. 9, 2010-09 ,pp. : 402-410

Joint Commission Resources

Access to resources Recommend Favorite

Genomic testing in cancer: Patient knowledge, attitudes, and expectations

CANCER, Vol. 120, Iss. 19, 2014-10 ,pp. : 3066-3073

John Wiley & Sons Inc

Access to resources Recommend Favorite

The ‘switcher’ patient profile in psoriasis treatment: from traditional to biological and from biological to traditional systemic drugs

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 1, 2015-07 ,pp. : 256-258

John Wiley & Sons Inc

Access to resources Recommend Favorite

Genomic Predictors of Outcome and Treatment Response in Breast Cancer

By Dunn Lara DeMichele Angela

Molecular Diagnosis & Therapy, Vol. 13, Iss. 2, 2009-04 ,pp. : 73-90

Adis International

Access to resources Recommend Favorite

Treatment of Venous Thrombosis in the Cancer Patient

Acta Haematologica, Vol. 106, Iss. 1-2, 2001-09 ,pp. : 81-87

Karger

Access to resources Recommend Favorite